- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04684719
Sangue Total Tipo O e Avaliação da Idade Durante o Teste de Ressuscitação Pré-hospitalar (TOWAR)
Sangue total tipo O e avaliação da idade durante o ensaio de ressuscitação pré-hospitalar (TOWAR)
Open label, multi-center, pre-hospital randomized trial utilizing 10 level-1 trauma centers designed to determine the efficacy and safety of low titer whole blood resuscitation as compared to component blood resuscitation in patients at risk of hemorrhagic shock and to appropriately characterize the hemostatic competency of whole blood relative to its age.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35294
- University of Alabama at Birmingham
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40292
- University of Louisville
-
-
Mississippi
-
Jackson, Mississippi, Estados Unidos, 39216
- University of Mississippi Medical Center (UMMC)
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45267
- University of Cincinatti
-
Cleveland, Ohio, Estados Unidos, 44109
- Metrohealth Systems
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15213
- University of Pittsburgh
-
-
Tennessee
-
Knoxville, Tennessee, Estados Unidos, 37920
- University of Tennessee Medical Center
-
Nashville, Tennessee, Estados Unidos, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- University of Texas Health Science Center at Houston
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98104
- University of Washington
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
1.) Injured patients at risk of hemorrhagic shock being transported from scene or referral hospital to a participating TOWAR trial site that meet requirements for initiation of blood or blood component transfusion
AND
2A.) Systolic blood pressure ≤ 90mmHg and tachycardia (HR ≥ 108) at scene, at outside hospital or during transport OR
2B.) Systolic blood pressure ≤ 70mmHg at scene, at outside hospital or during transport
Exclusion Criteria:
- Wearing NO TOWAR opt-out bracelet
- Age > 90 or < 18 years of age
- Isolated fall from standing injury mechanism
- Known prisoner or known pregnancy
- Traumatic arrest with > 5 minutes of CPR without return of vital signs
- Brain matter exposed or penetrating brain injury (GSW)
- Isolated drowning or hanging victims
- Objection to study voiced by subject or family member at the scene
- Inability to obtain IV or intraosseous access
- Isolated burns without evidence of traumatic injury
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Whole Blood
Subjects will receive up to two units of whole blood as collected by local blood bank procedures and stored at 1-6 degrees Celsius initiated in the prehospital phase of care. |
low titer whole blood, group O kept to either 21 days or 35 days based upon which preservation process is employed at each respective participating site |
|
Comparador Ativo: Component transfusion
Subjects will receive prehospital crystalloid infusion or blood component transfusion resuscitation per site standard care for the respective Emergency Medical unit/service. |
crystalloid infusion or blood component transfusion resuscitation |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
30 Day Mortality
Prazo: thru 30 days of enrollment
|
All cause mortality within 30 days |
thru 30 days of enrollment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
3-hour Mortality
Prazo: Enrollment through 3 hours
|
Death within 3 hours of enrollment |
Enrollment through 3 hours
|
|
6-hour Mortality
Prazo: Enrollment through 6 hours
|
Death within 6 hours of enrollment |
Enrollment through 6 hours
|
|
24-hour Mortality
Prazo: Enrollment through 24 hours
|
Death within 24 hours of enrollment |
Enrollment through 24 hours
|
|
In-hospital Mortality
Prazo: Enrollment through hospital discharge or 30 days
|
Death prior to hospital discharge |
Enrollment through hospital discharge or 30 days
|
|
Blood and Blood Component Transfusion Amount
Prazo: Enrollment through 24 hours
|
Number of units of blood or blood component transfused |
Enrollment through 24 hours
|
|
Multiple Organ Failure (MOF)
Prazo: Enrollment through 7 days or ICU discharge
|
Organ dysfunction will be evaluated via the Denver Post-injury Multiple Organ Failure Score. Patients who are never admitted to the Intensive Care Unit (ICU) or those with a length of ICU stay of less than 48 hours will be considered to have a Denver score of 0. A summary of the Denver score may be calculated by summing the worst scores of each of the individual systems over the course of the ICU stay. A summary Denver score > 3 will be classified as MOF. |
Enrollment through 7 days or ICU discharge
|
|
Hospital-acquired Pneumonia
Prazo: Number of participants who develop pneumonia through 30 days
|
Pneumonia acquired during hospitalization per Center for Disease Control (CDC) criteria |
Number of participants who develop pneumonia through 30 days
|
|
Blood Stream Infection
Prazo: Number of participants who develop blood stream infection through 30 days
|
Blood stream infection during hospitalization per CDC criteria |
Number of participants who develop blood stream infection through 30 days
|
|
Acute Respiratory Distress Syndrome (ARDS)
Prazo: Number of participants who develop ARDS through 30 days
|
The Berlin definition for mild ARDS (PaO2/FIO2, ≤ 300 mm Hg + timing, imaging and origin criteria) will be utilized as a threshold value to determine the incidence of ARDS and will be further stratified into Moderate (PaO2/FIO2, ≤ 200 mm Hg) and Severe (PaO2/FIO2, ≤ 100 mm Hg). |
Number of participants who develop ARDS through 30 days
|
|
Abnormal International Normalized Ratio (INR)
Prazo: Enrollment through 60 minutes
|
Measurement of platelet hemostatic function |
Enrollment through 60 minutes
|
|
Achievement of Hemostasis
Prazo: Enrollment through 4 hours
|
Ability to reach nadir transfusion requirement of 1 unit of red blood cells in a 60-minute time period in the first 4 hours following arrival |
Enrollment through 4 hours
|
|
Transfusion Reaction
Prazo: Enrollment through 24 hours
|
Any transfusion complication |
Enrollment through 24 hours
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Jason L Sperry, MD, University of Pittsburgh
Publicações e links úteis
Publicações Gerais
- Brunskill SJ, Disegna A, Wong H, Fabes J, Desborough MJ, Doree C, Davenport R, Curry N, Stanworth SJ. Blood transfusion strategies for major bleeding in trauma. Cochrane Database Syst Rev. 2025 Apr 24;4(4):CD012635. doi: 10.1002/14651858.CD012635.pub2.
- Meizoso JP, Cotton BA, Lawless RA, Kodadek LM, Lynde JM, Russell N, Gaspich J, Maung A, Anderson C, Reynolds JM, Haines KL, Kasotakis G, Freeman JJ. Whole blood resuscitation for injured patients requiring transfusion: A systematic review, meta-analysis, and practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg. 2024 Sep 1;97(3):460-470. doi: 10.1097/TA.0000000000004327. Epub 2024 Mar 27.
- Sperry JL, Guyette FX, Cotton BA, Luther JF, Utarnachitt RB, Kutcher ME, Daley BJ, Peetz AB, Patel MB, Goodman MD, Claridge JA, Patel N, Harbrecht BG, Hashmi ZG, Zarychanski R, Neal MD, Yazer MH, Martin-Gill C, Vincent LE, Harner AM, Meyer DE, Latimer AJ, Robinson BR, McKnight CL, Hinckley WR, Miller KR, Jansen JO, Martin D, Fox EE, Rosario-Rivera BL, Wisniewski SR; TOWAR Study Group. Prehospital Resuscitation with Type O Whole Blood for Trauma and Hemorrhage. N Engl J Med. 2026 Jun 18;394(23):2317-2328. doi: 10.1056/NEJMoa2602167. Epub 2026 May 18.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- STUDY20110430
- W81XWH-16-D-0024 (Número de outro subsídio/financiamento: Department of Defense)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
De-identified data may be shared with the funding agency as well as other researchers upon request to the Principal Investigator.
Prazo de Compartilhamento de IPD
Data will become available after publication of the primary manuscript.
Critérios de acesso de compartilhamento IPD
Requests for data will be submitted in writing and reviewed by the Principal Investigator.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- CIF
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .